ES2096686T3 - Fosfoinositolglicano-peptido con actividad tipo insulina. - Google Patents

Fosfoinositolglicano-peptido con actividad tipo insulina.

Info

Publication number
ES2096686T3
ES2096686T3 ES92113897T ES92113897T ES2096686T3 ES 2096686 T3 ES2096686 T3 ES 2096686T3 ES 92113897 T ES92113897 T ES 92113897T ES 92113897 T ES92113897 T ES 92113897T ES 2096686 T3 ES2096686 T3 ES 2096686T3
Authority
ES
Spain
Prior art keywords
phosphinositolglicano
peptido
type activity
insulin type
insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92113897T
Other languages
English (en)
Inventor
Gunter Dr Muller
Dominique Dr Tripier
Stefan Dr Mullner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Application granted granted Critical
Publication of ES2096686T3 publication Critical patent/ES2096686T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1027—Tetrapeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

SE DESCRIBEN PEPTIDOS DE FOSFOINOSITOLGLICANO OBTENIBLES MEDIANTE EL DESDOBLAMIENTO DE LA PROTEINA DE UNION DE ADENOSIN 3'',5'' CTOSA, MANOSA, INOSITOL, ACIDO FOSFORICO, ETANOLAMINA Y UN PEPTIDO CON LA SECUENCIA ASN CION PARA EL TRATAMIENTO DE LA DIABETES MELLITUS Y DIABETES NO DEPENDIENTE DE LA INSULINA.
ES92113897T 1991-08-20 1992-08-14 Fosfoinositolglicano-peptido con actividad tipo insulina. Expired - Lifetime ES2096686T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4127495 1991-08-20

Publications (1)

Publication Number Publication Date
ES2096686T3 true ES2096686T3 (es) 1997-03-16

Family

ID=6438668

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92113897T Expired - Lifetime ES2096686T3 (es) 1991-08-20 1992-08-14 Fosfoinositolglicano-peptido con actividad tipo insulina.

Country Status (22)

Country Link
US (1) US5624903A (es)
EP (1) EP0532915B1 (es)
JP (1) JP3361126B2 (es)
KR (2) KR100264623B1 (es)
AT (1) ATE147407T1 (es)
AU (1) AU656396B2 (es)
CA (1) CA2076424C (es)
CZ (1) CZ290341B6 (es)
DE (1) DE59207835D1 (es)
DK (1) DK0532915T3 (es)
ES (1) ES2096686T3 (es)
FI (1) FI102842B (es)
GR (1) GR3022895T3 (es)
HR (1) HRP940834B1 (es)
HU (1) HU210431B (es)
IL (1) IL102859A (es)
NO (1) NO303452B1 (es)
SG (1) SG46639A1 (es)
SK (1) SK281333B6 (es)
TW (1) TW224104B (es)
YU (1) YU66892A (es)
ZA (1) ZA926232B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0545198T3 (da) * 1991-11-29 2000-03-20 Hoechst Ag Peptider med insulinagtig virkning
DE59310171D1 (de) * 1992-02-29 2001-06-28 Aventis Res & Tech Gmbh & Co Komplexe enthaltend Glykosyl-Phosphatidylinositol-Proteine und Cholansäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung
US5652221A (en) * 1994-11-07 1997-07-29 The University Of Virginia Patent Foundation Method of treating defective glucose metabolism using synthetic insulin substances
GB9618929D0 (en) * 1996-09-11 1996-10-23 Univ London Metal containing carbohydrates from human tissue which regulate glycogen metabolism
GB9618934D0 (en) 1996-09-11 1996-10-23 Univ London Inositol phosphoglycans for therapeutic use in the treatment of diabetes and obesity
GB9618930D0 (en) * 1996-09-11 1996-10-23 Univ London Metal containing carbohydrates from human tissue which regulate lipogenic activity
KR100481746B1 (ko) * 1996-11-28 2005-08-10 훽스트 악티엔게젤샤프트 인슐린-유사작용을갖는이노시톨글리칸및이를포함하는약제학적제제
DE19649350A1 (de) * 1996-11-28 1998-06-04 Hoechst Ag Inositolglykane mit insulinartiger Wirkung
ATE298251T1 (de) 1998-08-06 2005-07-15 Mountain View Pharmaceuticals Peg-uricase konjugate und verwendung davon
CH697081A5 (de) * 2002-01-22 2008-04-30 Andreas F Dr Schaub Zusammensetzung für die Unterstützung der Geburt eines menschlichen Föten.
EP1378517A1 (en) * 2002-07-05 2004-01-07 Aventis Pharma Deutschland GmbH Phosphoinositolglycan (PIG) binding protein from adipocytes
AU2003248927A1 (en) * 2002-07-10 2004-01-23 Massachusetts Institute Of Technology Solid-phase and solution-phase synthesis of glycosylphosphatidylinositol glycans
ITMI20030237A1 (it) * 2003-02-11 2004-08-12 Indena Spa Uso della conglutina di lupino per il trattamento del
DE102004054552A1 (de) * 2004-11-11 2006-05-18 Hcb Happy Child Birth Holding Ag Neue Zusammensetzung zur Erleichterung der Humangeburt
MX2007012548A (es) 2005-04-11 2008-03-11 Savient Pharmaceuticals Inc Formas variantes de urato oxidasa y uso de las mismas.
KR20080009111A (ko) 2005-04-11 2008-01-24 새비언트 파마수티컬즈 인크. 유레이트 옥시다아제의 변이형 및 이의 용도
US8148123B2 (en) 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
JP2012531596A (ja) 2009-06-25 2012-12-10 サヴィエント・ファーマシューティカルズ・インコーポレイテッド Ｐｅｇ化ウリカーゼ療法における血清尿酸をモニタリングすることにより注入反応の危険性および抗体媒介性効果消失を予測するための方法およびキット
CN102270762B (zh) * 2010-06-03 2014-08-20 清华大学 锂离子电池电极浆料及应用该电极浆料制备的电极片
CN116637177A (zh) 2016-11-11 2023-08-25 好利恩治疗美国公司 泼尼松和尿酸酶分子的组合疗法及其用途
US12121566B2 (en) 2019-01-30 2024-10-22 Horizon Therapeutics Usa, Inc. Methods for treating gout
WO2020160325A1 (en) 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3326472A1 (de) * 1983-07-22 1985-02-14 Hoechst Ag, 6230 Frankfurt Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus
DE3326473A1 (de) * 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt Pharmazeutisches mittel zur behandlung des diabetes mellitus
US4906468A (en) * 1986-04-11 1990-03-06 The Rockefeller University Insulin activity messengers, their antibodies, and thereof
US4839466A (en) * 1986-04-11 1989-06-13 The Rockefeller University Insulin activity messengers

Also Published As

Publication number Publication date
CZ255392A3 (en) 1993-03-17
JPH05301891A (ja) 1993-11-16
EP0532915A2 (de) 1993-03-24
SK255392A3 (en) 1995-02-08
CA2076424A1 (en) 1993-02-21
GR3022895T3 (en) 1997-06-30
KR100264623B1 (ko) 2000-09-01
CA2076424C (en) 2003-06-03
HRP940834B1 (en) 2000-08-31
AU2110992A (en) 1993-02-25
IL102859A0 (en) 1993-01-31
ZA926232B (en) 1993-04-28
DK0532915T3 (da) 1997-07-07
HUT62013A (en) 1993-03-29
SK281333B6 (sk) 2001-02-12
FI923702L (fi) 1993-02-21
FI102842B1 (fi) 1999-02-26
HRP940834A2 (en) 1997-04-30
FI923702A0 (fi) 1992-08-18
HU210431B (en) 1995-04-28
IL102859A (en) 1998-12-27
ATE147407T1 (de) 1997-01-15
NO923252L (no) 1993-02-22
JP3361126B2 (ja) 2003-01-07
NO923252D0 (no) 1992-08-19
FI102842B (fi) 1999-02-26
AU656396B2 (en) 1995-02-02
NO303452B1 (no) 1998-07-13
SG46639A1 (en) 1998-02-20
YU66892A (sh) 1995-10-24
CZ290341B6 (cs) 2002-07-17
EP0532915B1 (de) 1997-01-08
DE59207835D1 (de) 1997-02-20
TW224104B (es) 1994-05-21
EP0532915A3 (en) 1994-05-18
KR930004327A (ko) 1993-03-22
KR100318706B1 (ko) 2001-12-28
US5624903A (en) 1997-04-29

Similar Documents

Publication Publication Date Title
DE3789413D1 (de) Lymphokin-ähnliche Peptide.
IT8619338A0 (it) Peptide sintetico ad attivita'interleukina 1 umana.
NO891711D0 (no) Hiv env-kodet peptid som er istand til aa fremkalle hiv-inhiberende antistoffer i pattedyr.
DK151985D0 (da) Humant fysiologisk aktivt polypeptid
NL194828B (nl) Somatostatinepeptiden, alsmede dergelijke somatostatinepeptiden bevattende farmaceutische preparaten.
IE823046L (en) Stabilised interferon formulations
DE3851238D1 (de) Antikoagulierende Peptide.
DE3786767D1 (de) Neues polypeptid.
DE3871169D1 (de) Dialyseloesung und ihre herstellung unter verwendung von peptiden auf der basis von glycin.
DE3686397D1 (de) Kovalent gebundene polypeptid enthaltende zellmodulatoren.
FI874596L (fi) Peptidpreparat.
DE68913970D1 (de) Schimärische peptide für die lieferung von neuropeptiden durch die blut-hirn-barriere.
FI871124L (fi) Polypeptid, dna och dess anvaendning.
NO167295C (no) Fremgangsmaate for fremstilling av et terapeutisk aktivt peptid.
DE3885313D1 (de) Peptide mit Laminin-Wirksamkeit.
GB8404708D0 (en) Polypeptide active immunosuppressant fraction
NL192192B (nl) Farmaceutische preparaten, die menselijk insuline en menselijk C-peptide bevatten.
EP0350318A3 (en) Novel peptides
IT1212790B (it) Peptidi biologicamente attivi.
CA2139571A1 (en) Interferon receptor binding peptides
DE3869939D1 (de) Biologisch wirksame peptide.
DK93683D0 (da) Biologisk aktive peptider
DE3685636D1 (de) Lysozymbetreffende peptide.
SE9402253D0 (sv) Process
IT1214444B (it) Peptidi biologicamente attivi.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 532915

Country of ref document: ES